

Supporting innovation in cardiovascular medicines and medical devices in the EU

EMA's contribution to the EU
Cardiovascular Health Plan

EMA multistakeholder workshop

01-02 July 2026



Supporting innovation in cardiovascular medicines and medical devices in the EU

Expected outcomes of the workshop

- Identify priority areas in research and innovation for cardiovascular (CV) prevention and treatment;
- Enhance collaboration between regulators, patients, healthcare professionals, academia, industry, and health technology assessment bodies;
- Improve understanding of scientific and regulatory gaps hindering CV research and innovation;
- Identify strategic recommendations to support development and timely access to safe and effective medicines and safe and performant medical devices for CV health;
- Provide foundations for follow-up actions, activities and initiatives.
- Hybrid meeting; live broadcast
- Registration starting from mid-February

Supporting innovation in cardiovascular medicines and medical devices in the EU

Draft agenda outline

- Session 1: Setting the scene
- Session 2: Opportunities in prevention and treatment
 - Part I: Cardiometabolic diseases: how to best tackle the unmet need in CV risk reduction
 - Part II: Innovation through personalised medicine
- Session 3: How can real-world data support innovation and decision-making in CV
- Session 4: Role of digitalisation and AI in CV innovation
- Eligible organisations and other relevant stakeholders will be approached for a call for speakers and panellists in February
- Registration starting from mid-February 2026; hybrid meeting; live broadcast



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

ivana.silva@ema.europa.eu

Follow us

